Akira Asai

Kana Shimizu

Koji Hasegawa

Masafumi Funamoto

Miho Yamada

Naohisa Ogo

Sari Nurmila

Satoshi Shimizu

Takahiro Katagiri

Tatsuya Morimoto

Yasufumi Katanasaka

Yoichi Sunagawa

Yusuke Miyazaki

European Cardiology Review

PubMed

Directory of Open Access Journals

ISCP Posters© RADCLIFFE CARDIOLOGY 2021Access at: www.ECRjournal.comIntroduction: Heart failure (HF) is one of the leading causes of death in the world. Although pharmacological therapies for HF, such as angiotensin 2 receptor blockers, angiotensin-converting enzyme inhibitors and β-blockers, are established, the mortality of patients with severe HF remains still high. The developing of the agent for HF therapy is strongly required. To identify a pharmacological therapy for HF, we developed a high throughput screening system using primary neonatal rat cardiomyocytes.Methods: Primary culture of neonatal rat cardiomyocytes were isolated and cultured on 48 well plates for 36 hours. These cells were treated with a library of 268 small molecules for 2 hours and stimulated with 30 μM PE for 48 hours. Cardiomyocytes were stained with an anti-α-actinin antibody, and nuclei were stained with Hoechst 33258. Immuno-fluorescence was detected and cardiomyocyte surface area was measured using ArrayScan® system. Inhibition rate was calculated using the following formula: Inhibition rate: (PE(+) − compound) / (PE(+) − PE(−)). Compounds of 50%-150% inhibition were classified as first hits. The already reported ones were excluded. In the second screening, the mRNA levels of hypertrophic response genes, such as ANF and BNP, were quantified by RT-PCR.Results: ArrayScan® system could automatically selected and evaluated the area of α-actinin-positive cardiomyocytes. 35 compounds were hits as inhibitor as cardiomyocyte hypertrophy. Eight compounds suppressed PE-induced hypertrophic response gene activations.Conclusion: We discovered eight small molecule inhibitors of cardiomyocyte hypertrophy by high throughput screening. Further animal examinations are needed to clarify the effects of these compounds on HF. Citation: European Cardiology Review 2021;16:e66. DOI: https://doi.org/10.15420/ecr.2021.16.PO10Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.Discovery of Novel Small Molecules for Heart Failure Therapy Using Cultured Cardiomyocyte by High Throughput Screening AssaySatoshi Shimizu,1,2 Miho Yamada,1 Takahiro Katagiri,1 Yoichi Sunagawa,1,2,3 Yasufumi Katanasaka,1,2,3 Yusuke Miyazaki,1,2,3 Masafumi Funamoto,1,2 Sari Nurmila,1 Kana Shimizu,1,2 Naohisa Ogo,4 Akira Asai,4 Koji Hasegawa1,2 and Tatsuya Morimoto1,2,31. Division of Molecular Medicine, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan;  2. Division of Translational Research, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan;  3. Shizuoka General Hospital, Shizuoka, Japan; 4. Centre for Drug Discovery, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan;

Discovery of Novel Small Molecules for Heart Failure Therapy Using Cultured Cardiomyocyte by High Throughput Screening Assay

https://assets.radcliffecardiology.com/s3fs-public/article-pdf/2021-12/ECR_ISCP_posters_2021_WEB_e66.pdf?VersionId=B_sb60Jit9Xdy_Z8_awQMK9saqOjDaWq

Discovery of Novel Small Molecules for Heart Failure Therapy Using Cultured Cardiomyocyte by High Throughput Screening Assay

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals